Welcome to our dedicated page for Oncolytics Biotech SEC filings (Ticker: ONCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oncolytics Biotech, Inc. (ONCY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent for pancreatic, breast, and gastrointestinal cancers. Its filings help investors understand how the company describes its programs, capital plans, and corporate structure.
Oncolytics files a range of documents, including Forms 6-K and 8-K that furnish or report material events and press releases. Recent 6-K reports have included information on the formation and expansion of a Gastrointestinal Tumor Scientific Advisory Board, progress toward pivotal and registration-directed studies in pancreatic, colorectal, and anal cancers, and details of an at-the-market sales agreement used to fund pelareorep’s clinical development and general corporate purposes. A Form 8-K has reported leadership appointments in strategy, operations, and biostatistics intended to support late-stage clinical execution.
Filings also describe corporate and jurisdictional changes, such as the proposed domestication from Alberta, Canada, to the State of Nevada in the United States, the company’s transition from foreign private issuer status to domestic issuer status, and related proxy and registration materials. These documents outline the rationale for reducing regulatory complexity, aligning domicile with U.S.-based operations and shareholders, and improving access to U.S. capital markets.
On Stock Titan, investors can review these SEC filings alongside AI-powered summaries that highlight key points, such as clinical trial plans, financing arrangements, and governance changes. Real-time updates from EDGAR, combined with AI explanations of complex documents like registration statements and current reports, help users quickly understand how ONCY’s regulatory disclosures relate to its immuno-oncology strategy and pelareorep development programs.
Oncolytics Biotech Inc. director Bernd R. Seizinger reported buying additional common shares of the company. On January 16, 2026, he acquired 100,000 common shares of Oncolytics Biotech at a weighted average price of $1.0377 per share, through multiple trades executed between $1.0294 and $1.0499.
Following this purchase, Seizinger beneficially owns 466,991 common shares, held directly. The filing notes that full detail on the number of shares bought at each individual price within the stated range is available upon request from the company, any security holder, or the SEC staff.
Oncolytics Biotech Inc. held a Special Meeting of Shareholders on January 15, 2026, where investors voted on key corporate changes. Shareholders representing 17,596,480 common shares, or 16.35% of the 107,606,376 shares outstanding as of the December 9, 2025 record date, were present or represented by proxy.
Investors approved a special resolution to continue the company from the Province of Alberta to the Province of British Columbia, and another special resolution to then domesticate the company from British Columbia to the State of Nevada in the United States. They also approved the Oncolytics Biotech Inc. 2026 Incentive Award Plan, each proposal receiving more votes for than against.
The company later issued a press release announcing these results, which has been filed as an exhibit and incorporated by reference into its Form F-3 registration statement.
Oncolytics Biotech, Inc. filed a current report to disclose leadership changes. The company announced that John McAdory has been appointed as Executive Vice President of Strategy and Operations and Yujun Wu has been appointed as Vice President, Head of Biostatistics, signaling additions to its senior management team.
The company also states that this report on Form 8-K, including the attached press release, is incorporated by reference as an exhibit to its Registration Statement on Form F-3 (File No. 333-289819). No financial results or major transactions are described in this report.
Oncolytics Biotech, Inc. filed a Form 8-K to highlight two recent developments related to its cancer therapy pelareorep. On January 8, 2026, the company issued a press release describing updates to its intellectual property portfolio and efforts to extend patent protection for pelareorep as part of its long-term value and development strategy. On January 12, 2026, it released updated clinical data from the GOBLET Cohort 4 study, which showed activity of pelareorep combined with atezolizumab in third-line anal cancer.
The company is also using this report, including the two press releases attached as Exhibits 99.1 and 99.2, as an exhibit to its existing shelf Registration Statement on Form F-3. This helps ensure that the patent and clinical updates are formally included in the broader disclosure framework the company uses for potential future securities offerings.
Oncolytics Biotech Inc. filed a Form 6-K that includes a press release announcing three new members to its gastrointestinal Tumor Scientific Advisory Board: Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris. These globally recognized GI oncologists will advise on the development of pelareorep, the company’s investigational immunotherapy, across pancreatic, colorectal, and anal cancers.
The company highlights aggregated clinical data suggesting higher overall survival and response rates for pelareorep-based regimens versus historical benchmarks in first-line pancreatic cancer, squamous cell anal carcinoma, and KRAS-mutant metastatic colorectal cancer. Oncolytics states it is planning pivotal studies in all three indications, intends to continue engaging with the FDA where needed, and notes that its metastatic pancreatic and breast cancer programs with pelareorep have received Fast Track designation.
FAQ
What is the current stock price of Oncolytics Biotech (ONCY)?
What is the market cap of Oncolytics Biotech (ONCY)?
